Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury (Hour 2) 40 min · 24 Sep 2026 · Rahimi & Grote Show

Cubs squander chance to clinch playoff berth in losing to Marlins, 3-2 (Hour 1) 42 min · 24 Sep 2026 · Rahimi & Grote Show

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury 19 min · 24 Sep 2026 · Rahimi & Grote Show

710: That New Mouse Pad Feeling 2h 13m · 24 Sep 2026 · Accidental Tech Podcast

Steven Bartlett REVEALS the Secret Behind the World’s Fastest Growing Podcast | PBD Podcast #861 1h 27m · 24 Sep 2026 · PBD Podcast

1PM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded19 Sep 2023

Publisherc.answersincme.com ↗

Handlerec:10296342

Show notes

Please visit answersincme.com/CAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses the use of neoadjuvant-adjuvant immunotherapy to improve outcomes in patients with resectable melanoma. Upon completion of this activity, participants should be better able to: Review the rationale for the use of neoadjuvant-adjuvant immunotherapy for patients with resectable melanoma; Describe the clinical profiles of the emerging neoadjuvant-adjuvant immunotherapeutic regimens in patients with resectable melanoma; and Identify patients for whom a neoadjuvant-adjuvant approach may be appropriate based on available clinical evidence.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in